Physician profile
Thomas Suczewski
NPI 1750424180
$1,184.03
in general payments reported to CMS, 2019-2025
21 companies · $86.60 in 2025
The $86.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $321 · 2021: $328 · 2022: $127 · 2023: $102 · 2024: $28.69 · 2025: $86.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.90 | 2020-2023 | |
| Allergan, INC. | $143.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $134.82 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $123.20 | 2019-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $99.78 | 2022-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $57.50 | 2020-2021 | |
| Abbvie INC. | $55.59 | 2021 | |
| Astellas Pharma US INC | $53.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.69 | 2021 | |
| Sunovion Pharmaceuticals INC. | $45.97 | 2022 | |
| Nabriva Therapeutics, Plc | $41.78 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $36.80 | 2021 | |
| Exact Sciences Corporation | $32.47 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $30.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.18 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.11 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.64 | 2019 | |
| Amgen INC. | $18.83 | 2025 | Repatha |
| Lilly USA, LLC | $14.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.19 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Suczewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.